Navigation Links
FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer
Date:10/19/2009

nths of median PFS with VOTRIENT versus 4.2 months with placebo.

The most common adverse events occurring in greater than or equal to 20% of subjects treated with VOTRIENT included diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting. Grade 3/4 adverse events among these toxicities that differed by greater than or equal to 2% included abnormal liver function, hypertension, diarrhea, asthenia, and abdominal pain. Laboratory abnormalities occurring in >10% of patients and more commonly (greater than or equal to 5%) in the pazopanib arm included increased transaminases, hyperglycemia, leukopenia, hyperbilirubinemia, neutropenia, hypophosphatemia, thrombocytopenia, lymphocytopenia, hyponatremia, hypomagnesemia, and hypoglycemia. Drug-related deaths were observed in 1.4% of 290 patients and included hepatic failure (n=2), stroke (n=1), and perforation (n=1). Hepatic dysfunction is included as a boxed warning in the product label. Other Warnings and Precautions in the label relate to QT prolongation and torsade de pointes, hemorrhagic events, arterial thrombotic events, gastrointestinal perforation and fistula, hypertension, impaired wound healing, hypothyroidism, proteinuria, and pregnancy.

VOTRIENT has a broad clinical program across multiple tumor types, with study details available at www.clinicaltrials.gov. More than 2,000 patients have been treated to date in clinical trials. VOTRIENT is not yet approved in any country other than the U.S.

About GSK Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
2. FDA Approves New Treatment for Advanced Form of Kidney Cancer
3. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
4. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
5. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
6. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
7. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
10. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
11. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   Fruit Street Health (Fruit Street), today ... of funding. The round, which includes ... of individual investors, the majority of whom are prominent ... round are; Houston Cardiology Consultants Partner Asif Ali, ... Rapha Family Medicine Practice Owner Frances Ilozue , ...
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
(Date:9/18/2014)... Research conducted by a team of ... has documented improved survival in patients with cancerous ... tumors along with stereotactic radiosurgery. , The study was ... (American Society for Radiation Oncology) this week in San ... radiation beams to treat tumors in the brain, delivering ...
(Date:9/18/2014)... and London. (PRWEB) September 18, 2014 ... Computer Aided Engineering software, today announced its new partnership ... be utilizing the CD-adapco simulation tool, STAR-CCM+® in the ... just announced its participation in the 35th America’s Cup ... 35th edition of the America’s Cup is sustainability, the ...
Breaking Medicine News(10 mins):Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2
... studying rare genetic disorders have uncovered insights into ... when cells divide. Focusing on the cohesin complex, ... encircles chromosome pairs, scientists have discovered mutations that ... diseases called cohesinopathies. "We are learning more ...
... Israel; Seoul, South Korea, May 29, 2012 -- The ... enabled an Israeli-South Korean scientific team to conduct a genetic ... B virus (HBV) genotype C2 sequence common in Southeast Asia. ... be used as a model to study the evolution of ...
... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
... battle: Long after a cancer has been beaten into remission, it ... is unclear. New research led by Weizmann Institute scientists shows that, ... cancer recurrence is in a set of cells that do not ... survive chemotherapy. The findings, which appeared today in the journal ...
... not healthy. However, new research from the University of Copenhagen ... vitamin is not good either. The study is based on ... published in the reputed scientific Journal of Clinical Endocrinology ... calcium reach our bones, thus lessening the risk from falls ...
... , MONDAY, May 28 (HealthDay News) -- Women who work ... increasing their risk for breast cancer, Danish researchers find. ... women who describe themselves as "morning" people rather than "evening" ... of women in modern societies have night shift work," said ...
Cached Medicine News:Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: